Prominent Study

The BBRC is part of the PROMINENT consortium, a public-private collaboration, funded by the Innovative Health Initiative for a period of five years, which brings together experts in neurodegenerative diseases and clinical neuroscience, artificial intelligence, health economics and patient advocacy. The project partners also include some of Europe's leading medical centers for the diagnosis and treatment of cognitive disorders.  The project will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities. The overriding objective is to assist clinicians with individualised decision support in the evaluation of patients with suspected cognitive impairment.

The project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112145. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio MedTech Europe, Vaccines Europe, BioArctic AB and Combinostics Oy.​